Characterizing a phenomenon in GBM patients who do not respond well to immunotherapy
The changing landscape of NSCLC diagnosis, monitoring and treatment
Immunotherapy in second-line treatment of non-small cell lung cancer
HOPA 2018 updates on urothelial carcinoma: what is new?
How effective is pembrolizumab in cisplatin-ineligible bladder cancer? Results from KEYNOTE-052